New study tracks how zuranolone affects postpartum depression in real life

NCT ID NCT07398469

Recruiting now Symptom relief Sponsor: Biogen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 200 people with postpartum depression who are starting zuranolone (Zurzuvae). Researchers will use online surveys to track symptom changes at 15, 45, and 90 days. The goal is to see how symptoms improve in everyday conditions, not in a controlled lab setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zuranolone (Zurzuvae)
What this could lead to: If successful, this study could show that zuranolone helps reduce postpartum depression symptoms in real-world settings.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by factors other than the drug. It is also relatively small (200 participants) and relies on self-reported data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTPARTUM DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postpartum depression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTPARTUM DEPRESSION

Contacts and locations

Locations

Biogen
RECRUITING

Cambridge, Massachusetts, 02142, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.